title: In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy.
abstract: The use of antiretroviral combination therapy in HIV has been associated with lipodystrophy and several metabolic risk factors. We postulated that patients with HIV-lipodystrophy have impaired adipose tissue free fatty acid (FFA) trapping and, consequently, increased hepatic FFA delivery. We investigated FFA, hydroxybutyric acid (HBA; reflecting hepatic FFA oxidation), and triglyceride (TG) changes after a high fat meal in HIV-infected males with (LIPO; n = 26) and without (NONLIPO; n = 12) lipodystrophy and in healthy males (n = 35). Because defective peripheral FFA trapping has been associated with impaired action of complement component 3 (C3), we also determined postprandial C3 concentrations. The LIPO group had higher homeostasis model assessment scores compared with the other groups. Areas under the curve (AUCs) for FFA, HBA, and TG were higher in the LIPO group than in the NONLIPO group or the controls. No differences in TG-AUC, FFA-AUC, and HBA-AUC were observed between the NONLIPO group and controls. In HIV-infected patients, FFA-AUC and HBA-AUC were inversely related to sc adipose tissue area. Plasma C3 showed a postprandial increase in healthy controls, but not in the HIV-infected groups. C3 was not related to body fat distribution, postprandial FFA, or HBA. The present data suggest disturbed postprandial FFA metabolism in patients with HIV-lipodystrophy, most likely due to inadequate incorporation of FFA into TG in sc adipose tissue, but do not support a major role for C3 in these patients. The higher postprandial HBA levels reflect increased hepatic FFA delivery and may aggravate insulin resistance and dyslipidemia, leading to increased cardiovascular risk.
authors.affiliation: Department of Internal Medicine, University Medical Center Utrecht, G02.402, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. j.p.h.vanwijk@azu.nl
authors.forename: J P H
authors.initials: JP
authors.lastname: van Wijk
authors.forename: M Castro
authors.initials: MC
authors.lastname: Cabezas
authors.forename: E J P
authors.initials: EJ
authors.lastname: de Koning
authors.forename: T J
authors.initials: TJ
authors.lastname: Rabelink
authors.forename: R
authors.initials: R
authors.lastname: van der Geest
authors.forename: I M
authors.initials: IM
authors.lastname: Hoepelman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005215:Fasting; D005227:Fatty Acids / Q000378:metabolism*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D014057:Tomography, X-Ray Computed; D014280:Triglycerides / Q000097:blood*
chemical_list: D005227:Fatty Acids; D008074:Lipoproteins; D014280:Triglycerides